Diverticulitis is NOT a contraindication to GLP-1 medications
Diverticulitis does not appear in any published guidelines or drug labels as a contraindication to GLP-1 receptor agonists, and there is no evidence linking these medications to worsening diverticular disease or increased risk of diverticulitis.
Key Evidence
The most comprehensive recent guidelines on GLP-1 receptor agonist use 1, 2 do not list diverticulitis among contraindications or conditions requiring caution. The primary gastrointestinal concerns with GLP-1 RAs relate to:
- Delayed gastric emptying (relevant for aspiration risk during procedures)
- Acute pancreatitis (use with caution in patients with history of pancreatitis) 2
- Gastrointestinal side effects (nausea, vomiting, diarrhea, constipation)
Gastrointestinal Safety Profile
Recent systematic reviews demonstrate that GLP-1 RAs increase risk of:
- Cholelithiasis (RR 1.46; 2 additional cases per 1000 patients) 3
- GERD (RR 2.19; 4 additional cases per 1000 patients) 3
However, GLP-1 RAs do not increase risk of other gastrointestinal events including intestinal obstruction, gastrointestinal perforation, gastrointestinal ischemia, or gastrointestinal ulceration 3.
Potential Benefits for Intestinal Disease
Emerging research suggests GLP-1 may have beneficial effects on intestinal diseases through anti-inflammatory properties and effects on gut motility 4. While this research is preliminary, it provides no signal of harm in diverticular disease.
Clinical Considerations
The main gastrointestinal adverse effects are dose-dependent and include:
- Nausea, vomiting, diarrhea, constipation (47-84% vs 13-63% with placebo) 5
- Most are mild-to-moderate and improve with slow titration 2
- Discontinuation due to adverse events occurs in 0-26% of patients 5
Common pitfall to avoid: Do not confuse general gastrointestinal side effects with specific contraindications. The presence of diverticulitis (active or history of) should not prevent initiation or continuation of GLP-1 RA therapy when otherwise indicated for diabetes or weight management.
If a patient with diverticulitis requires GLP-1 therapy, proceed with standard dosing and titration protocols. Monitor for typical GLP-1 side effects (nausea, diarrhea, constipation) but these are not specific to or worsened by underlying diverticular disease.